论文部分内容阅读
目的:探讨东菱迪芙治疗急性脑梗死患者的临床疗效及安全性。方法:随机将收治的80例急性脑梗死患者分为治疗组40例,对照组40例。2组均给予抗血小板聚集、钙拮抗剂等基础治疗,并将血塞通0.25g加入0.9%氯化钠溶液或5%葡萄糖溶液250ml中静脉点滴,连用14d。在此基础上,治疗组于治疗第1、3、5d给予东菱迪芙10、5、5U加入0.9%氯化钠溶液250ml中静脉滴注,每次滴注时间不少于1h。观察2组疗效,治疗前后神经功能缺损评分及于治疗前后测定血浆FIB水平并测定其疗效。结果:治疗组显效率(75.00%)明显高于对照组(47.50%)(P<0.05),神经功能缺损评分明显低于对照组(P<0.05),治疗组FIB由治疗前(3.98±0.86)g/L,降至(1.84±0.42)g/L,治疗前后有显著性差异(P<0.01)。结论:东菱迪芙通过降低血浆FIB,增强纤溶活性,降低血黏度,改善脑循环等综合作用,对急性脑梗死疗效显著、安全性好,值得推广应用。
Objective: To investigate the clinical efficacy and safety of Donglingdufu in patients with acute cerebral infarction. Methods: 80 cases of acute cerebral infarction were randomly divided into treatment group 40 cases, control group 40 cases. 2 groups were given anti-platelet aggregation, calcium antagonists and other basic treatment, and Xuesaitong 0.25g added 0.9% sodium chloride solution or 5% glucose solution 250ml intravenous drip for 14d. On this basis, the treatment group on the 1st, 3rd and 5th d were given Donglingdufu 10,5,5 U plus 0.9% sodium chloride solution 250ml intravenous infusion, each infusion time of not less than 1h. The curative effect of two groups were observed, the score of neurological deficit before and after treatment and the level of plasma FIB before and after treatment were measured. Results: The markedly effective rate (75.00%) in the treatment group was significantly higher than that in the control group (47.50%) (P <0.05), and the score of neurological deficit in the treatment group was significantly lower than that in the control group (3.98 ± 0.86 ) g / L to (1.84 ± 0.42) g / L, there was a significant difference before and after treatment (P <0.01). Conclusion: Donglingdufu can reduce the plasma FIB, enhance the fibrinolytic activity, reduce the blood viscosity, improve the cerebral circulation and other comprehensive effects. It has significant curative effect on acute cerebral infarction and good safety. It is worth popularizing and applying.